The biotech industry continues to push the limits of innovation, developing groundbreaking therapies that improve patient outcomes. However, even the most promising companies run into the same wall: scaling production and bringing products to market is difficult. Partnering with a Contract Development and Manufacturing Organization (CDMO) can help biotech companies navigate these hurdles.
Why Scaling Biotech Manufacturing Is So Complex
Manufacturing biotech products is inherently complex. It demands sophisticated production processes, specialized equipment, and tightly controlled environments. And moving from clinical-scale to commercial-scale production only adds to the difficulty. On top of that, companies must maintain compliance with current Good Manufacturing Practices (cGMPs) established by regulatory bodies such as the FDA and EMA, a requirement that becomes more demanding as operations grow.
For biotech startups, the challenge is compounded by limited resources. Scaling up calls for:
- Building and maintaining manufacturing facilities
- Hiring specialized talent
- Managing increasingly complex supply chains
These are substantial, non-negotiable investments, and for smaller companies, they often slow the scaling process.
Biotech Commercialization Challenges and Market Access Barriers
Getting a product to market can be complex on its own. Biotech companies have to navigate:
- Regulatory approval processes (which differ greatly by region and country)
- Market entry strategies
- Pricing negotiations
- Safe, efficient product delivery — including cold chain logistics where required
Supply chains have also become less global and more localized in recent years. As Risk & Insurance notes, the biotech industry largely sourced materials globally before the pandemic, but pandemic-era travel restrictions left many manufacturers unable to access the raw materials they needed. These constraints resulted in shorter supply chains and a greater need for tight logistical control.
How CDMO Partnerships Support Biotech Scaling and Commercialization
CDMOs bring the technical and regulatory expertise that biotech companies need to scale efficiently. Because they’re deeply versed in cGMPs, they help guarantee compliance by:
- Assisting with documentation and submission processes
- Supporting compliance audits
- Keeping up with distribution, regulatory standing, and market penetration as companies grow
Beyond compliance, there are practical advantages to working with a CDMO. They give companies access to state-of-the-art facilities and technology without the capital investment required to build them in-house, and their solutions can be flexible as a company’s needs change. CDMOs also typically manage the full supply chain, from raw material sourcing to distribution, as well as robust analytical testing and stability programs during scale-up.
One of the most important ways working with a CDMO can support is freeing up internal resources, which means biotech companies can redirect focus toward:
- Research and development
- Clinical trials
- Marketing and go-to-market strategy
All of which adds up to a faster time-to-market.
Afton Scientific Can Help You Address Your Scaling and Commercialization Challenges
Scaling and commercialization remain two of the biggest hurdles in biotech. Partnering with Afton Scientific as your CDMO gives you access to the expertise, resources, and support needed to clear them — whether that means streamlining manufacturing, ensuring regulatory compliance, optimizing resource allocation, or shaping an effective marketing strategy. If you’re ready to scale and commercialize your products, contact us to learn more.